


I

and pharmaceutically acceptable salts thereof.

In one aspect there is provided a compound of structural Formula I:

5



I

or a pharmaceutically acceptable salt thereof, wherein

~~A is heteroaryl or heteroaryl fused to a saturated or unsaturated 5- or 6-membered ring containing 0-3 heteroatoms independently selected from O, S and N(R^h)_q, wherein each heteroaryl, 5-membered ring and 6-membered ring is unsubstituted or substituted with one to five substituents selected from R^a;~~

A is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine,
- (3) pyrazine,
- (4) indazole,
- (5) imidazo[1,2-a]pyridine,
- (6) pyrrolo[3,2-c]pyridine,
- (7) pyrrolo[2,3-b]pyridine,
- (8) pyrazole,
- (9) thiophene, and
- (10) 1,2,4-oxadiazole,

wherein A is unsubstituted or substituted with one to four substituents selected from R^a;

B is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents selected from R^b;

R^1 is selected from the group consisting of:

- (1) —hydrogen,
- (2) — SO_3H ,
- (3) — SO_2NH_2 ,
- (4) — $SO_2NReC_{1-6}alkyl$,
- (5) — $SO_2NReC(O)C_{1-6}alkyl$,
- (6) — $SO_2NReC_{2-6}alkenyl$,
- (7) — $SO_2NReC_{3-6}cycloalkyl$,
- (8) — $SO_2NReC(O)C_{3-6}cycloalkyl$,
- (9) — $SO_2NReC_{2-6}cycloheteroalkyl$,
- (10) — $SO_2NReC(O)C_{2-6}cycloheteroalkyl$,
- (11) — $SO_2NRe-aryl$,
- (12) — $SO_2NRe-heteroaryl$,
- (13) — $SO_2C_{1-6}alkyl$,
- (14) — $SO_2C_{1-6}alkenyl$,
- (15) — $SO_2C_{3-6}cycloalkyl$,
- (16) — $SO_2C_{2-6}cycloheteroalkyl$,
- (17) — SO_2aryl ,
- (18) — $SO_2heteroaryl$,
- (19) — $S(O)R^j$,
- (20) — SR^j ,
- (21) — $C(O)NH_2$,
- (22) — $C(O)NReR^j$,
- (23) — CO_2H ,
- (24) — CO_2R^j ,
- (25) — $C(O)R^j$,
- (26) — CN ,
- (27) — CF_3 ,
- (28) —halogen,
- (29) — OH ,
- (30) — $OC_{1-6}alkyl$,
- (31) — $OC_{2-6}alkenyl$,
- (32) — $OC_{3-6}cycloalkyl$,
- (33) — $OC_{2-6}cycloheteroalkyl$,
- (34) — $O-aryl$,
- (35) — $O-heteroaryl$,
- (36) — $OC(O)R^j$,

- (37) $\text{OC(O)NR}^e\text{R}^j$;
 (38) $\text{OC(O)N(R}^j)_2$;
 (39) $\text{C}_{1-6}\text{alkyl}$;
 (40) $\text{C}_{2-6}\text{alkenyl}$;
 (41) $\text{C}_{1-6}\text{cycloalkyl}$;
 (42) $\text{C}_{2-6}\text{cycloheteroalkyl}$;
 (43) aryl ;
 (44) heteroaryl ;
 (45) $(\text{CH}_2)_n\text{NR}^e\text{C(O)R}^j$;
 (46) $(\text{CH}_2)_n\text{NR}^e\text{C(O)OR}^j$;
 (47) $(\text{CH}_2)_n\text{NR}^e\text{C(O)N(R}^e)_2$;
 (48) $(\text{CH}_2)_n\text{NR}^e\text{C(O)NR}^e\text{R}^j$;
 (49) $(\text{CH}_2)_n\text{NR}^e\text{C(O)N(R}^j)_2$;
 (50) $(\text{CH}_2)_n\text{NR}^e\text{S(O)}_m\text{R}^j$;
 (51) $(\text{CH}_2)_n\text{NR}^e\text{S(O)}_m\text{N(R}^e)_2$;
 (52) $(\text{CH}_2)_n\text{NR}^e\text{S(O)}_m\text{NR}^e\text{R}^j$;
 (53) $(\text{CH}_2)_n\text{NR}^e\text{S(O)}_m\text{N(R}^j)_2$; and
 (54) $(\text{CH}_2)_n\text{NR}^e\text{R}^j$;

wherein each CH_2 , alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to four substituents selected from R^d ; R^1 is selected from the group consisting of:

- (1) $-\text{SO}_2\text{NH}_2$;
 (2) $-\text{SO}_2\text{C}_{1-6}\text{alkyl}$;
 (3) $-\text{SO}_2\text{NH-C}_{1-6}\text{alkyl}$;
 (4) $-\text{SO}_2\text{C}_{3-6}\text{cycloalkyl}$;
 (5) $-\text{C(O)NH}_2$;
 (6) $-\text{CO}_2\text{H}$;
 (7) $-\text{CN}$;
 (8) halogen;
 (9) $-\text{OH}$;
 (10) $-\text{OC}_{1-6}\text{alkyl}$, and
 (11) $-\text{C}_{1-6}\text{alkyl}$;

wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one substituent selected from R^d ;

R^2 is selected from the group consisting of:

- (1) hydrogen, and
 (2) $-\text{C}_{1-6}\text{alkyl}$;

R³ is selected from the group consisting of:

- (1) a monocyclic, bicyclic or spirocyclic C₃₋₁₂cycloalkyl ring, and
- (2) a monocyclic, bicyclic or spirocyclic C₂₋₁₂cycloheteroalkyl ring,

wherein the cycloheteroalkyl contains 1-4 heteroatoms independently selected from N(R^m)_r, O,

5 and S, wherein each cycloalkyl ring and each cycloheteroalkyl ring may be fused to an aryl or heteroaryl, and wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to eight substituents selected from R^C;

each R^a is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- 10 (2) -OC₁₋₆alkyl,
- (3) halogen,
- (4) -OH,
- (5) oxo,
- (6) -CN,
- 15 (7) -C₃₋₆cycloalkyl, and
- (8) -C₂₋₅cycloheteroalkyl,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to six substituents selected from halogen, OH, NH₂, NH(C₁₋₆alkyl) and N(C₁₋₆alkyl)₂;

~~each R^b is independently selected from the group consisting of:~~

- 20 ~~(1) —CF₃,~~
- ~~(2) —CF₂CF₃,~~
- ~~(3) —CHF₂,~~
- ~~(4) —OCHF₂,~~
- ~~(5) —OCH₂CF₃,~~
- 25 ~~(6) —OCF₃,~~
- ~~(7) —CN,~~
- ~~(8) —halogen,~~
- ~~(9) —Si(C₁₋₆alkyl)₃,~~
- ~~(10) —C₁₋₆alkyl-O-R^k,~~
- 30 ~~(11) —C₁₋₆alkyl,~~
- ~~(12) —C₂₋₆alkenyl,~~
- ~~(13) —C₂₋₆alkynyl,~~
- ~~(14) —C₃₋₆cycloalkyl,~~
- ~~(15) —C₂₋₆cycloheteroalkyl,~~
- 35 ~~(16) —aryl,~~
- ~~(17) —heteroaryl,~~
- ~~(18) —C₁₋₆alkyl-C₃₋₆cycloalkyl,~~

- (19) —C₁₋₆alkyl-C₂₋₆cycloheteroalkyl,
 (20) —C₁₋₆alkyl-aryl,
 (21) —C₁₋₆alkyl-heteroaryl,
 (22) —C₂₋₆alkenyl-C₃₋₆cycloalkyl,
 (23) —C₂₋₆alkenyl-C₂₋₆cycloheteroalkyl,
 (24) —C₂₋₆alkenyl-aryl,
 (25) —C₂₋₆alkenyl-heteroaryl,
 (26) —C₂₋₆alkynyl-C₃₋₆cycloalkyl,
 (27) —C₂₋₆alkynyl-cycloheteroalkyl,
 (28) —C₂₋₆alkynyl-aryl,
 (29) —C₂₋₆alkynyl-heteroaryl,
 (30) —NO₂,
 (31) —OH,—
 (32) —(CH₂)_p-OC₁₋₆alkyl,
 (33) —(CH₂)_p-OC₂₋₆alkenyl,
 (34) —(CH₂)_p-OC₂₋₆alkynyl,
 (35) —(CH₂)_p-OC₃₋₆cycloalkyl,
 (36) —(CH₂)_p-OC₂₋₆heterocycloalkyl,
 (37) —(CH₂)_p-O-aryl,
 (38) —(CH₂)_p-O-heteroaryl,
 (39) —OC₁₋₆alkyl-C₃₋₆cycloalkyl,
 (40) —OC₁₋₆alkyl-C₂₋₆heterocycloalkyl,
 (41) —OC₁₋₆alkyl-aryl,
 (42) —OC₁₋₆alkyl-heteroaryl,
 (1) —S(O)_mR^k,
 (43) —C₁₋₆alkyl-S(O)_mR^k,
 (44) —C(O)R^k,
 (45) —N(Rⁱ)₂, and
 (46) —NRⁱR^k,

wherein each R^b is unsubstituted or substituted with one to five substituents selected from R^f;
 each R^b is independently selected from the group consisting of:

- (1) —CF₃,
 (2) —CHF₂,
 (3) —OCHF₂,
 (4) —OCH₂CF₃,
 (5) —OCF₃,
 (6) —CN,

- (7) F,
 (8) Cl,
 (9) Br,
 (10) -CH₃,
 (11) -C(CH₃)₃,
 (12) -OCH₃,
 (13) cyclopropyl,
 (14) cyclobutyl,
 (15) piperidine,
 (16) -CH₂-cyclopropyl,
 (17) -C₂alkynyl-cyclopropyl, and
 (18) pyrazole,

wherein each R^b is unsubstituted or substituted with one to five substituents selected from R^f;
 each R^c is independently selected from the group consisting of:

- (1) —CF₃,
 (2) —CH₂CF₃,
 (3) —CHF₂,
 (4) —OCHF₂,
 (5) —OCF₃,
 (6) —CN,
 (7) —oxo,
 (8) —OH,
 (9) —halogen,
 (10) —C₁alkyl,
 (11) —C₂alkenyl,
 (12) —C₂alkynyl,
 (13) —C₃cycloalkyl,
 (14) —C₂cycloheteroalkyl,
 (15) —C₁alkyl-C₃cycloalkyl,
 (16) —C₁alkyl-C₂cycloheteroalkyl,
 (17) —C₁alkyl-aryl,
 (18) —C₁alkyl-heteroaryl,
 (19) —C₁alkenyl-C₃cycloalkyl,
 (20) —C₁alkenyl-aryl,
 (21) —C₁alkenyl heteroaryl,
 (22) —C₁alkenyl-C₂cycloheteroalkyl,
 (23) —C₂alkynyl-C₃cycloalkyl,

(24) ~~C₂₋₆alkynyl-C₂₋₆cycloheteroalkyl,~~

(25) ~~C₂₋₆alkynyl-aryl,~~

(26) ~~C₂₋₆alkynyl-heteroaryl,~~

(27) ~~OC₁₋₆alkyl,~~

(28) ~~OC₂₋₆alkenyl,~~

(29) ~~OC₂₋₆alkynyl,~~

(30) ~~OC₃₋₆cycloalkyl,~~

(31) ~~OC₂₋₆heterocycloalkyl,~~

(32) ~~O-aryl,~~

(33) ~~O-heteroaryl,~~

(34) ~~OC₁₋₆alkyl-cycloalkyl,~~

(35) ~~OC₁₋₆alkyl-cycloheteroalkyl,~~

(36) ~~OC₁₋₆alkyl-aryl,~~

(37) ~~OC₁₋₆alkyl-heteroaryl,~~

(38) ~~S(O)_mR^L,~~

(39) ~~S(O)R^L,~~

(40) ~~S-R^L,~~

(41) ~~C₁₋₆alkyl-S(O)_mR^L,~~

(42) ~~C(O)R^L,~~

(43) ~~C(O)C₁₋₆alkyl-R^L,~~

(44) ~~OC(O)R^L,~~

(45) ~~CO₂R^L,~~

(46) ~~aryl, and~~

(47) ~~heteroaryl,~~

~~wherein each R^C is unsubstituted or substituted with one to five substituents selected from R^G;~~
each R^C is independently selected from the group consisting of:

(1) -CF₃,

(2) -CH₂CF₃,

(3) -CHF₂,

(4) -OCF₃,

(5) CN,

(6) halogen,

(7) -C₁₋₆alkyl,

(8) oxo,

(9) -OH,

(10) -C₁₋₆alkyl-OH,

(11) -O-aryl,

- (12) -O-heteroaryl,
- (13) aryl,
- (14) heteroaryl,
- (15) -C₁₋₆alkyl-aryl, and
- (16) -C₁₋₆alkyl-heteroaryl,

wherein each R^c is unsubstituted or substituted with one to five substituents selected from R^g;

R^d is independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) OH,
- (4) oxo,
- (5) -C₁₋₆alkyl,
- (6) -OC₁₋₆alkyl,
- (7) NH₂,
- (8) NH(C₁₋₆alkyl), and
- (9) N(C₁₋₆alkyl)₂;

each R^e is independently selected from the group consisting of:

- (1) hydrogen, and
- (2) -C₁₋₆alkyl;

each R^f is selected from the group consisting of:

- (1) halogen, F
- (2) -C₁₋₆alkyl,
- (3) -OH,
- (4) -OC₁₋₆alkyl,
- (5) -OC₃₋₆cycloalkyl,
- (6) -OC₂₋₆cycloheteroalkyl,
- (7) CN,
- (8) -NH₂,
- (9) -NH(C₁₋₆alkyl),
- (10) -NH(C₃₋₆cycloalkyl),
- (11) -NH(C₂₋₆cycloheteroalkyl),
- (12) -N(C₁₋₆alkyl)₂,
- (13) -N(C₃₋₆cycloalkyl)₂, and
- (14) -N(C₂₋₆cycloheteroalkyl)₂,

wherein each alkyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;

each R^g is selected from the group consisting of:

- (1) halogen,
 - (2) C₁₋₆alkyl,
 - (3) -OH,
 - (4) -OC₁₋₆alkyl,
 - 5 (5) -S(O)_m-C₁₋₆alkyl,
 - (6) -CN,
 - (7) -CF₃,
 - (8) -OCHF₂, and
 - (9) -OCF₃,
- 10 wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;
- each R^h is independently selected from the group consisting of:
- (1) hydrogen, and
 - (2) -C₁₋₆alkyl;
- 15 each Rⁱ is independently selected from the group consisting of:
- (1) hydrogen, and
 - (2) -C₁₋₆alkyl;
- each R^j is selected from the group consisting of:
- (1) -C₁₋₆alkyl,
 - 20 (2) -C₂₋₆alkenyl,
 - (3) -C₃₋₆cycloalkyl,
 - (4) -C₂₋₆cycloheteroalkyl,
 - (5) aryl, and
 - (6) heteroaryl,
- 25 wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;
- each R^k is selected from the group consisting of:
- (1) -C₁₋₆alkyl,
 - 30 (2) -C₂₋₆alkenyl,
 - (3) -C₃₋₆cycloalkyl,
 - (4) -C₃₋₆cycloalkyl,
 - (5) -C₂₋₆cycloheteroalkyl,
 - (6) aryl, and
 - 35 (7) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

each R^L is selected from the group consisting of:

- 5 (1) -C₁₋₆alkyl,
 (2) -C₂₋₆alkenyl,
 (3) -C₃₋₆cycloalkyl,
 (4) -C₂₋₆cycloheteroalkyl,
 (5) aryl, and
10 (6) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

each R^M is independently selected from the group consisting of:

- 15 (1) hydrogen, and
 (2) -C₁₋₆alkyl;

each n is independently 0, 1, 2, 3 or 4;

each m is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3 or 4;

20 each q is independently 0 or 1; and

each r is independently 0 or 1.

In another aspect, there is provided a compound selected from:

- 1) 2-(4,4-difluoropiperidin-1-yl)-N-(6-sulfamoylpyrazin-2-yl)-5-(trifluoromethyl)-nicotinamide;
25 2) 2-(4,4-difluoropiperidin-1-yl)-N-(4-hydroxypyrimidin-2-yl)-5-(trifluoromethyl)-nicotinamide;
3) 5-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
4) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
5) N-(6-cyanopyridin-3-yl)-2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamide;
30 6) 2-(azepan-1-yl)-N-(5-(methylsulfonyl)pyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
7) 2-(3-(hydroxymethyl)piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
8) 2-(azepan-1-yl)-N-(5-carbamoylpyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
9) 2-(4,4-difluoro-1-piperidyl)-6-methyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
35 10) 5-chloro-2-(4,4-difluoro-1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
11) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(5-sulfamoylpyridin-3-yl)nicotinamide;

- 12) 5,6-dicyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 13) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 5 14) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 15) 5-cyclobutyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 10 16) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 17) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 18) 6-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 19) 2-(4,4-difluoroazepan-1-yl)-5,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 15 20) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide;
- 21) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 22) 6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 20 23) 5-chloro-6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 24) 6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 25) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 25 26) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 27) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-nicotinamide;
- 28) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30 29) 2-(4,4-Dichloropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 31) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;
- 35 32) 5-chloro-2-(4,4-difluoroazepan-1-yl)-4,6-dimethyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;

- 33) N-{1-[(2-aminoethyl)sulfonyl]-1H-pyrazol-4-yl}-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methylpyridine-3-carboxamide;
- 34) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-indazol-3-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 5 35) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 36) N-[1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 10 37) N-[5-cyclopropyl-1-(methylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 38) 2-cyclopropyl-4-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;
- 39) 6-cyclopropyl-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyridazine-4-carboxamide;
- 15 40) 6-methyl-N-(2-sulfamoylpyridin-4-yl)-2-(3,4,4-trifluoroazepan-1-yl)nicotinamide;
- 41) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 42) N-[2-(tert-butylsulfamoyl)pyridin-4-yl]-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-pyridine-3-carboxamide;
- 20 43) 5-cyano-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;
- 44) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 45) 2-(azepan-1-yl)-N-(3-cyano-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 25 46) 5-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 47) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 30 48) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 49) (R)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 50) (S)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 35 51) 2-(4,4-Dichloroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

- 52) 2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 53) 5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-6-methyl-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 5 54) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 55) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 10 56) (S)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 57) (R)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 58) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1S,5S)-1-(trifluoromethyl)-3-azabicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;
- 15 59) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1R,5R)-1-(trifluoromethyl)-3-azabicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;
- 60) N-(2-sulfamoylpyridin-4-yl)-2-((1R,5S)-6,6,7,7-tetrafluoro-3-azabicyclo[3.2.0]heptan-3-yl)-5-(trifluoromethyl)nicotinamide;
- 61) 2-[(1S,6S)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 62) 2-[(1R,6R)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 63) 2-((1R,5S)-8,8-difluoro-3-oxaoctan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 25 64) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 65) 2-((1S,5R)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 66) (R)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 30 67) (S)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 68) 2-((1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 35 69) 2-((1S,6S)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

- 70) 2-((1R,6R)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 71) 2-[(1R,4R)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 5 72) 2-[(1S,4S)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 73) (R)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 74) (S)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 10 75) 2-((3R,4s,5S)-4-hydroxy-3,4,5-trimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 76) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 77) 2-[(3S,4S)-4-hydroxy-3-methyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 78) 2-[(3S,4r,5R)-4-hydroxy-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 79) 2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 20 80) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 81) 2-[3-(3,5-difluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 25 82) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 83) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[[4-(trifluoromethyl)phenyl]methyl]-1-piperidyl]pyridine-3-carboxamide;
- 84) N-(2-sulfamoyl-4-pyridyl)-2-thiomorpholino-5-(trifluoromethyl)pyridine-3-carboxamide;
- 30 85) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridine-3-carboxamide;
- 86) 2-(3-benzyl-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 87) 2-[3,3-dimethyl-4-(2,2,2-trifluoroethyl)piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 88) 2-(2,2-dimethylmorpholin-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 89) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[8-(trifluoromethyl)-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-3-carboxamide;
- 90) N-(2-sulfamoyl-4-pyridyl)-2-[4-(trifluoromethoxy)isoindolin-2-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 5 91) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[2-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyridine-3-carboxamide;
- 92) N-(2-sulfamoyl-4-pyridyl)-2-(3,3,4,4-tetrafluoropyrrolidin-1-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 93) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)azetidin-1-yl]pyridine-3-carboxamide;
- 10 94) 2-(3-pyrazol-1-ylpyrrolidin-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 95) 2-[2-(4-fluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 15 96) 2-(2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 97) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenoxy]azetidin-1-yl]pyridine-3-carboxamide;
- 98) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-[3-(trifluoromethyl)phenoxy]-1-piperidyl]pyridine-3-carboxamide;
- 20 99) 2-[4-(cyclopropylmethyl)-3-oxo-piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 100) N-(2-sulfamoyl-4-pyridyl)-2-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 25 101) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 102) 2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 103) 2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 30 104) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 105) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 106) 2-[(2R)-6,6-dimethyl-2-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 107) 2-(2,2-dimethyl-1,4-oxazepan-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

	<u>108) 2-[(7S)-7-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;</u>
	<u>109) N-[2-(tert-butylsulfamoyl)-4-pyridyl]-5-chloro-2-(4,4-difluoroazepan-1-yl)pyridine-3-carboxamide;</u>
5	<u>110) 2-[(2S)-2-methylmorpholin-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>111) 2-[(2R)-2-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;</u>
10	<u>112) 2-(3-hydroxy-3-methyl-1-piperidyl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>113) 2-(6-fluoro-1,1-dimethyl-isoindolin-2-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;</u>
	<u>114) 2-(azepan-1-yl)-N-(2-methyl-5-sulfamoylthiophen-3-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
15	<u>115) 2-(4,4-difluoro-5-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;</u>
	<u>116) 5-chloro-2-[(7R)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;</u>
20	<u>117) 5-chloro-2-[(7S)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;</u>
	<u>118) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;</u>
	<u>119) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;</u>
25	<u>120) 2-[(2S,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>121) 2-((2R,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
30	<u>122) 2-((2R,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>123) 2-((2S,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>124) (S)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;</u>
35	<u>125) (R)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;</u>

	<u>126) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;</u>
	<u>127) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)nicotinamide;</u>
5	<u>128) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;</u>
	<u>129) (S)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;</u>
10	<u>130) (R)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;</u>
	<u>131) 2-(4,4-difluoro-3-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;</u>
	<u>132) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;</u>
15	<u>133) 2-((2R,6S)-2-ethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>134) 2-((2S,6R)-2-ethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
20	<u>135) (R)-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>136) (S)-2-(2,2-dimethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>137) 4-(2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;</u>
	<u>138) 6-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;</u>
25	<u>139) 2-(azepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>140) 2-(azepan-1-yl)-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>141) 2-(azepan-1-yl)-N-(6-sulfamoyl-2-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>142) 2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
30	<u>143) N-(2-methoxypyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>144) 2-(4,4-difluoroazepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>145) 2-(azepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
35	<u>146) 2-(4,4-difluoroazepan-1-yl)-N-(2-methoxy-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>

	<u>147) 2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-(methylsulfonyl)pyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	<u>148) 2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoro-</u> <u>methyl)-pyridine-3-carboxamide;</u>
5	<u>149) 2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoro-</u> <u>methyl)-pyridine-3-carboxamide;</u>
	<u>150) N-(2-cyano-4-pyridyl)-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-5-(trifluoro-</u> <u>methyl)-pyridine-3-carboxamide;</u>
10	<u>151) N-(2-methylsulfonyl-4-pyridyl)-2-[(1R,5S)-6,6,7,7-tetrafluoro-3-</u> <u>azabicyclo[3.2.0]heptan-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>152) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-methylsulfonyl-4-pyridyl)-5-</u> <u>(trifluoromethyl)pyridine-3-carboxamide;</u>
	<u>153) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-cyano-4-pyridyl)-5-</u> <u>(trifluoromethyl)pyridine-3-carboxamide;</u>
15	<u>154) (R)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-</u> <u>nicotinamide;</u>
	<u>155) (S)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-</u> <u>nicotinamide;</u>
20	<u>156) 4-(2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)-</u> <u>picolinamide;</u>
	<u>157) N-(2-carbamoyl-4-pyridyl)-2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-5-</u> <u>(trifluoromethyl)-pyridine-3-carboxamide;</u>
	<u>158) N-(2-carbamoyl-4-pyridyl)-2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-5-</u> <u>(trifluoromethyl)-pyridine-3-carboxamide;</u>
25	<u>159) 2-(4,4-difluoropiperidin-1-yl)-4-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>160) 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-</u> <u>sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>161) 5-chloro-6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-</u> <u>sulfamoylpyridin-4-yl)nicotinamide;</u>
30	<u>162) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoro-</u> <u>methyl)nicotinamide;</u>
	<u>163) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoro-</u> <u>methyl)nicotinamide;</u>
35	<u>164) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-</u> <u>(trifluoromethyl)nicotinamide;</u>
	<u>165) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-</u> <u>(trifluoromethyl)nicotinamide;</u>

	<u>166) 6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>167) 6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
5	<u>168) 6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>169) 5-chloro-6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
10	<u>170) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>171) 2-(4,4-difluoroazepan-1-yl)-5-(difluoromethoxy)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>172) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
15	<u>173) 4-(4,4-difluoroazepan-1-yl)-2-methyl-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;</u>
	<u>174) 2-(4,4-difluoroazepan-1-yl)-6-(difluoromethyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	<u>175) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
20	<u>176) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)pyridine-2-sulfonic acid;</u>
	<u>177) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethoxy)nicotinamide</u>
	<u>178) 2-(4,4-difluoropiperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
25	<u>179) 3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide;</u>
	<u>180) 5-(tert-butyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;</u>
30	<u>181) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;</u>
	<u>182) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethoxy)-nicotinamide;</u>
35	<u>183) 2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(2,2,2-trifluoroethoxy)-nicotinamide;</u>
	<u>184) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;</u>

5	185)	<u>6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;</u>
	186)	<u>2-(azepan-1-yl)-N-(5-fluoropyridin-3-yl)-5-(trifluoromethyl)nicotinamide;</u>
	187)	<u>2-(azepan-1-yl)-5-chloro-N-(2-methoxy-4-pyridyl)-4,6-dimethyl-pyridine-3-carboxamide;</u>
	188)	<u>2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;</u>
	189)	<u>5-chloro-2-(4,4-difluoro-1-piperidyl)-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;</u>
10	190)	<u>2-(6-azaspiro[2.5]octan-6-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;</u>
	191)	<u>5-chloro-4,6-dimethyl-2-(1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;</u>
	192)	<u>2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;</u>
15	193)	<u>2-(azepan-1-yl)-N-(5-cyano-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	194)	<u>2-(azepan-1-yl)-N-(5-methoxy-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	195)	<u>2-(azepan-1-yl)-N-(5-methyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
20	196)	<u>2-(azepan-1-yl)-N-[5-(hydroxymethyl)-3-pyridyl]-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	197)	<u>2-(azepan-1-yl)-N-(2-cyano-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	198)	<u>2-(azepan-1-yl)-N-(2-ethylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
	199)	<u>2-(azepan-1-yl)-N-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;</u>
25	200)	<u>2-(azepan-1-yl)-5-(trifluoromethyl)-N-[5-(trifluoromethyl)-3-pyridyl]pyridine-3-carboxamide;</u>
	201)	<u>2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	202)	<u>5-chloro-4,6-dimethyl-2-(6-azaspiro[2.5]octan-6-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	203)	<u>4-(2-(azepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;</u>
30	204)	<u>5-bromo-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	205)	<u>2-(4,4-difluoropiperidin-1-yl)-5-phenyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
	206)	<u>2-(4,4-difluoropiperidin-1-yl)-5-(piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;</u>
35		

207) 2-(4,4-difluoropiperidin-1-yl)-5-(1H-pyrazol-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;

208) N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)-nicotinamide;

209) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)nicotinamide;

210) 2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;

211) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(piperidin-1-yl)nicotinamide;

212) 2-(azepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)nicotinamide; and

213) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound selected from:

1) 5-chloro-2-(4,4-difluorocyclohexyl)-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

2) 5-chloro-2-cycloheptyl-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide

3) 5-chloro-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrazine-2-carboxamide;

4) 5-chloro-4,6-dimethyl-2-(4-methylcyclohexyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide; and

5) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N,4,6-trimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

or a pharmaceutically acceptable salt thereof.

The compounds of structural formula I, and embodiments thereof, are inhibitors of $Na_v1.8$ sodium ion channel activity (or $Na_v1.8$ inhibitors) and may be useful in the treatment and prevention of diseases, disorders and conditions mediated by $Na_v1.8$ sodium ion channel activity, such as nociception, osteoarthritis, peripheral neuropathy, inherited erythromelalgia, multiple sclerosis, asthma, itch, atopy, allergic or contact dermatitis, renal failure, cholestasis, pruritus, acute itch, chronic itch, migraine, neurodegeneration following ischemia, epilepsy, pain, inflammatory pain, spontaneous pain, acute pain, acute pain due to fractures, musculoskeletal damage, pancreatitis and renal colic, peri-operative pain, post-operative pain, neuropathic pain, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, chronic lower back pain, phantom limb pain, sciatica, pain caused by 2° or 3° burn injury, optic neuritis, pain resulting from cancer and chemotherapy, chronic pelvic pain, pain syndromes, and complex regional pain syndromes. In one example of the present disclosure, the condition, disease or disorder is a pain

disorder, an acute pain disorder or chronic pain disorder. In another example of the present disclosure, the condition, disease or disorder is an acute pain disorder.

The present disclosure also relates to pharmaceutical compositions comprising the compounds of the present disclosure and a pharmaceutically acceptable carrier. In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure also relates to methods for the treatment, management, prevention, alleviation, amelioration, suppression or control of disorders, diseases, and conditions that may be responsive to inhibition of Na_v1.8 sodium ion channel activity in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present disclosure.

The present disclosure also relates to the use of compounds of the present disclosure for manufacture of a medicament useful in treating diseases, disorders and conditions that may be responsive to the inhibition of Na_v1.8 sodium ion channel activity. ~~In another aspect, there is provided use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of Nav1.8 channel activity in a mammal in need thereof.~~ In another aspect, there is provided use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

In another aspect, there is provided a compound as defined herein, or a pharmaceutically acceptable salt thereof, for use in therapy.

The present disclosure is also concerned with treatment or prevention of these diseases, disorders and conditions by administering the compounds of the present disclosure in combination with a therapeutically effective amount of another agent that may be useful to treat the disease, disorder and condition. The disclosure is further concerned with processes for preparing the compounds of this disclosure.

In another aspect, there is provided a compound selected from:

1) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

2) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

3) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;

4) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

5) 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

- 6) 5-chloro-6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 7) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 8) 2-(4,4-difluoroazepan-1-yl)-6-(difluoromethyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 9) 2-(4,4-difluoropiperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 10) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 11) 5-chloro-6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 12) 4-(2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
- 13) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; and
- 14) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound which is (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide; or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound which is (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide; or a pharmaceutically acceptable salt thereof.


In another aspect, there is provided a compound which is 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide; or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound which is 2-(4,4-difluoro-piperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a compound which is 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS:

1. A compound of structural Formula I:



or a pharmaceutically acceptable salt thereof, wherein

~~A is heteroaryl or heteroaryl fused to a saturated or unsaturated 5- or 6-membered ring containing 0-3 heteroatoms independently selected from O, S and N(R^h)_q, wherein each heteroaryl, 5-membered ring and 6-membered ring is unsubstituted or substituted with one to five substituents selected from R^a;~~

A is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine,
- (3) pyrazine,
- (4) indazole,
- (5) imidazo[1,2-a]pyridine,
- (6) pyrrolo[3,2-c]pyridine,
- (7) pyrrolo[2,3-b]pyridine,
- (8) pyrazole,
- (9) thiophene, and
- (10) 1,2,4-oxadiazole,

wherein A is unsubstituted or substituted with one to four substituents selected from R^a;

B is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to three substituents selected from R^b;

~~R¹ is selected from the group consisting of:~~

- ~~(1) hydrogen,~~
- ~~(2) SO₃H,~~

	(3) — SO_2NH_2 ,
	(4) — $\text{SO}_2\text{NReC}_{1-6}\text{alkyl}$,
	(5) — $\text{SO}_2\text{NReC}(\text{O})\text{C}_{1-6}\text{alkyl}$,
	(6) — $\text{SO}_2\text{NReC}_{2-6}\text{alkenyl}$,
5	(7) — $\text{SO}_2\text{NReC}_{3-6}\text{cycloalkyl}$,
	(8) — $\text{SO}_2\text{NReC}(\text{O})\text{C}_{3-6}\text{cycloalkyl}$,
	(9) — $\text{SO}_2\text{NReC}_{2-6}\text{cycloheteroalkyl}$,
	(10) — $\text{SO}_2\text{NReC}(\text{O})\text{C}_{2-6}\text{cycloheteroalkyl}$,
	(11) — $\text{SO}_2\text{NRe-aryl}$,
10	(12) — $\text{SO}_2\text{NRe-heteroaryl}$,
	(13) — $\text{SO}_2\text{C}_{1-6}\text{alkyl}$,
	(14) — $\text{SO}_2\text{C}_{1-6}\text{alkenyl}$,
	(15) — $\text{SO}_2\text{C}_{3-6}\text{cycloalkyl}$,
	(16) — $\text{SO}_2\text{C}_{2-6}\text{cycloheteroalkyl}$,
15	(17) — SO_2aryl ,
	(18) — $\text{SO}_2\text{heteroaryl}$,
	(19) — $\text{S}(\text{O})\text{R}^j$,
	(20) — SR^j ,
	(21) — $\text{C}(\text{O})\text{NH}_2$,
20	(22) — $\text{C}(\text{O})\text{NReR}^j$,
	(23) — CO_2H ,
	(24) — CO_2R^j ,
	(25) — $\text{C}(\text{O})\text{R}^j$,
	(26) — CN ,
25	(27) — CF_3 ,
	(28) — halogen,
	(29) — OH ,
	(30) — $\text{OC}_{1-6}\text{alkyl}$,
	(31) — $\text{OC}_{2-6}\text{alkenyl}$,
30	(32) — $\text{OC}_{3-6}\text{cycloalkyl}$,
	(33) — $\text{OC}_{2-6}\text{cycloheteroalkyl}$,
	(34) — O-aryl ,
	(35) — O-heteroaryl ,
	(36) — $\text{OC}(\text{O})\text{R}^j$,
35	(37) — $\text{OC}(\text{O})\text{NReR}^j$,
	(38) — $\text{OC}(\text{O})\text{N}(\text{R}^j)_2$,
	(39) — $\text{C}_{1-6}\text{alkyl}$, —

- (40) —C₂₋₆alkenyl,
 (41) —C₁₋₆cycloalkyl,
 (42) —C₂₋₆cycloheteroalkyl,
 (43) —aryl,
 (44) —heteroaryl,
 (45) —(CH₂)_nNReC(O)R^j,
 (46) —(CH₂)_nNReC(O)OR^j,
 (47) —(CH₂)_nNReC(O)N(Re)₂,
 (48) —(CH₂)_nNReC(O)NReR^j,
 (49) —(CH₂)_nNReC(O)N(R^j)₂,
 (50) —(CH₂)_nNReS(O)_mR^j,
 (51) —(CH₂)_nNReS(O)_mN(Re)₂,
 (52) —(CH₂)_nNReS(O)_mNReR^j,
 (53) —(CH₂)_nNReS(O)_mN(R^j)₂, and
 (54) —(CH₂)_nNReR^j,

wherein each CH₂, alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to four substituents selected from R^d;

R¹ is selected from the group consisting of:

- (1) —SO₂NH₂,
 (2) —SO₂C₁₋₆alkyl,
 (3) —SO₂NH-C₁₋₆alkyl,
 (4) —SO₂C₃₋₆cycloalkyl,
 (5) —C(O)NH₂,
 (6) —CO₂H,
 (7) —CN,
 (8) halogen,
 (9) —OH,
 (10) —OC₁₋₆alkyl, and
 (11) —C₁₋₆alkyl,

wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one substituent selected from R^d;

R² is selected from the group consisting of:

- (1) hydrogen, and
 (2) —C₁₋₆alkyl;

R³ is selected from the group consisting of:

- (1) a monocyclic, bicyclic or spirocyclic C₃₋₁₂cycloalkyl ring, and
- (2) a monocyclic, bicyclic or spirocyclic C₂₋₁₂cycloheteroalkyl ring,

wherein the cycloheteroalkyl contains 1-4 heteroatoms independently selected from N(R^m)_r, O,

5 and S, wherein each cycloalkyl ring and each cycloheteroalkyl ring may be fused to an aryl or heteroaryl, and wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to eight substituents selected from R^C;

each R^a is selected from the group consisting of:

- 10 (1) -C₁₋₆alkyl,
- (2) -OC₁₋₆alkyl,
- (3) halogen,
- (4) -OH,
- (5) oxo,
- 15 (6) -CN,
- (7) -C₃₋₆cycloalkyl, and
- (8) -C₂₋₅cycloheteroalkyl,

wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to six substituents selected from halogen, OH, NH₂, NH(C₁₋₆alkyl) and N(C₁₋₆alkyl)₂;

20

~~each R^b is independently selected from the group consisting of:~~

- ~~(1) —CF₃,~~
- ~~(2) —CF₂CF₃,~~
- ~~(3) —CHF₂,~~
- 25 ~~(4) —OCHF₂,~~
- ~~(5) —OCH₂CF₃,~~
- ~~(6) —OCF₃,~~
- ~~(7) —CN,~~
- ~~(8) —halogen,~~
- 30 ~~(9) —Si(C₁₋₆alkyl)₃,~~
- ~~(10) —C₁₋₆alkyl-O-R^k,~~
- ~~(11) —C₁₋₆alkyl,~~
- ~~(12) —C₂₋₆alkenyl,~~
- ~~(13) —C₂₋₆alkynyl,~~
- 35 ~~(14) —C₃₋₆cycloalkyl,~~
- ~~(15) —C₂₋₆cycloheteroalkyl,~~
- ~~(16) —aryl,~~

- (17) ~~heteroaryl,~~
 (18) ~~C₁₋₆alkyl-C₃₋₆cycloalkyl,~~
 (19) ~~C₁₋₆alkyl-C₂₋₆cycloheteroalkyl,~~
 (20) ~~C₁₋₆alkyl-aryl,~~
 (21) ~~C₁₋₆alkyl-heteroaryl,~~
 (22) ~~C₂₋₆alkenyl-C₃₋₆cycloalkyl,~~
 (23) ~~C₂₋₆alkenyl-C₂₋₆cycloheteroalkyl,~~
 (24) ~~C₂₋₆alkenyl-aryl,~~
 (25) ~~C₂₋₆alkenyl-heteroaryl,~~
 (26) ~~C₂₋₆alkynyl-C₃₋₆cycloalkyl,~~
 (27) ~~C₂₋₆alkynyl-cycloheteroalkyl,~~
 (28) ~~C₂₋₆alkynyl-aryl,~~
 (29) ~~C₂₋₆alkynyl-heteroaryl,~~
 (30) ~~NO₂,~~
 (31) ~~OH,~~
 (32) ~~(CH₂)_p-OC₁₋₆alkyl,~~
 (33) ~~(CH₂)_p-OC₂₋₆alkenyl,~~
 (34) ~~(CH₂)_p-OC₂₋₆alkynyl,~~
 (35) ~~(CH₂)_p-OC₃₋₆cycloalkyl,~~
 (36) ~~(CH₂)_p-OC₂₋₆heterocycloalkyl,~~
 (37) ~~(CH₂)_p-O-aryl,~~
 (38) ~~(CH₂)_p-O-heteroaryl,~~
 (39) ~~OC₁₋₆alkyl-C₃₋₆cycloalkyl,~~
 (40) ~~OC₁₋₆alkyl-C₂₋₆heterocycloalkyl,~~
 (41) ~~OC₁₋₆alkyl-aryl,~~
 (42) ~~OC₁₋₆alkyl-heteroaryl,~~
 (1) ~~S(O)_mR^k,~~
 (43) ~~C₁₋₆alkyl-S(O)_mR^k,~~
 (44) ~~C(O)R^k,~~
 (45) ~~N(Rⁱ)₂, and~~
 (46) ~~NRⁱR^k,~~

~~wherein each R^b is unsubstituted or substituted with one to five substituents selected from R^f;~~

each R^b is independently selected from the group consisting of:

- (1) -CF₃,
 (2) -CHF₂,
 (3) -OCHF₂,

- (4) -OCH₂CF₃,
- (5) -OCF₃,
- (6) CN,
- (7) F,
- (8) Cl,
- (9) Br,
- (10) -CH₃,
- (11) -C(CH₃)₃,
- (12) -OCH₃,
- (13) cyclopropyl,
- (14) cyclobutyl,
- (15) piperidine,
- (16) -CH₂-cyclopropyl,
- (17) -C₂alkynyl-cyclopropyl, and
- (18) pyrazole,

wherein each R^b is unsubstituted or substituted with one to five substituents selected from R^f;

each R^c is independently selected from the group consisting of:

- (1) ~~—CF₃,~~
- (2) ~~—CH₂CF₃,~~
- (3) ~~—CHF₂,~~
- (4) ~~—OCHF₂,~~
- (5) ~~—OCF₃,~~
- (6) ~~—CN,~~
- (7) ~~—oxo,~~
- (8) ~~—OH,~~
- (9) ~~—halogen,~~
- (10) ~~—C₁₋₆alkyl,~~
- (11) ~~—C₂₋₆alkenyl,~~
- (12) ~~—C₂₋₆alkynyl,~~
- (13) ~~—C₃₋₆cycloalkyl,~~
- (14) ~~—C₂₋₆cycloheteroalkyl,~~
- (15) ~~—C₁₋₆alkyl-C₃₋₆cycloalkyl,~~
- (16) ~~—C₁₋₆alkyl-C₂₋₆cycloheteroalkyl,~~
- (17) ~~—C₁₋₆alkyl-aryl,~~
- (18) ~~—C₁₋₆alkyl-heteroaryl,~~
- (19) ~~—C₁₋₆alkenyl-C₃₋₆cycloalkyl,~~

- (20) —C₁₋₆alkenyl-aryl,
 (21) —C₁₋₆alkenyl heteroaryl,
 (22) —C₁₋₆alkenyl-C₂₋₆cycloheteroalkyl,
 (23) —C₂₋₆alkynyl-C₃₋₆cycloalkyl,
 (24) —C₂₋₆alkynyl-C₂₋₆cycloheteroalkyl,
 (25) —C₂₋₆alkynyl-aryl,
 (26) —C₂₋₆alkynyl heteroaryl,
 (27) —OC₁₋₆alkyl,
 (28) —OC₂₋₆alkenyl,
 (29) —OC₂₋₆alkynyl,
 (30) —OC₃₋₆cycloalkyl,
 (31) —OC₂₋₆heterocycloalkyl,
 (32) —O-aryl,
 (33) —O-heteroaryl,
 (34) —OC₁₋₆alkyl-cycloalkyl,
 (35) —OC₁₋₆alkyl-cycloheteroalkyl,
 (36) —OC₁₋₆alkyl-aryl,
 (37) —OC₁₋₆alkyl-heteroaryl,
 (38) —S(O)_mR^L,
 (39) —S(O)R^L,
 (40) —S-R^L,
 (41) —C₁₋₆alkyl-S(O)_mR^L,
 (42) —C(O)R^L,
 (43) —C(O)C₁₋₆alkyl-R^L,
 (44) —OC(O)R^L,
 (45) —CO₂R^L,
 (46) —aryl, and
 (47) —heteroaryl,

wherein each R^E is unsubstituted or substituted with one to five substituents selected from R^G;

each R^C is independently selected from the group consisting of:

- (1) —CF₃,
 (2) —CH₂CF₃,
 (3) —CHF₂,
 (4) —OCF₃,
 (5) —CN,
 (6) —halogen,

- (7) -C₁₋₆alkyl,
- (8) oxo,
- (9) -OH,
- (10) -C₁₋₆alkyl-OH,
- (11) -O-aryl,
- (12) -O-heteroaryl,
- (13) aryl,
- (14) heteroaryl,
- (15) -C₁₋₆alkyl-aryl, and
- (16) -C₁₋₆alkyl-heteroaryl,

wherein each R^c is unsubstituted or substituted with one to five substituents selected from R^g;

R^d is independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) OH,
- (4) oxo,
- (5) -C₁₋₆alkyl,
- (6) -OC₁₋₆alkyl,
- (7) NH₂,
- (8) NH(C₁₋₆alkyl), and
- (9) N(C₁₋₆alkyl)₂;

each R^e is independently selected from the group consisting of:

- (1) hydrogen, and
- (2) -C₁₋₆alkyl;

each R^f is selected from the group consisting of:

- (1) halogen, F
- (2) -C₁₋₆alkyl,
- (3) -OH,
- (4) -OC₁₋₆alkyl,
- (5) -OC₃₋₆cycloalkyl,
- (6) -OC₂₋₆cycloheteroalkyl,
- (7) CN,
- (8) -NH₂,
- (9) -NH(C₁₋₆alkyl),

- (10) -NH(C₃-6cycloalkyl),
- (11) -NH(C₂-6cycloheteroalkyl),
- (12) -N(C₁-6alkyl)₂,
- (13) -N(C₃-6cycloalkyl)₂, and
- (14) -N(C₂-6cycloheteroalkyl)₂,

wherein each alkyl, cycloalkyl, and cycloheteroalkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;

each R^g is selected from the group consisting of:

- (1) halogen,
- (2) C₁-6alkyl,
- (3) -OH,
- (4) -OC₁-6alkyl,
- (5) -S(O)_m-C₁-6alkyl,
- (6) -CN,
- (7) -CF₃,
- (8) -OCHF₂, and
- (9) -OCF₃,

wherein each alkyl is unsubstituted or substituted with one to three substituents independently selected from: -OH, halogen, cyano, and -S(O)₂CH₃;

each R^h is independently selected from the group consisting of:

- (1) hydrogen, and
- (2) -C₁-6alkyl;

each Rⁱ is independently selected from the group consisting of:

- (1) hydrogen, and
- (2) -C₁-6alkyl;

each R^j is selected from the group consisting of:

- (1) -C₁-6alkyl,
- (2) -C₂-6alkenyl,
- (3) -C₃-6cycloalkyl,
- (4) -C₂-6cycloheteroalkyl,
- (5) aryl, and
- (6) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

5 each R^k is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆alkenyl,
- (3) -C₃₋₆cycloalkyl,
- (4) -C₃₋₆cycloalkyl,
- 10 (5) -C₂₋₆cycloheteroalkyl,
- (6) aryl, and
- (7) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

15

each R^L is selected from the group consisting of:

- (1) -C₁₋₆alkyl,
- (2) -C₂₋₆alkenyl,
- 20 (3) -C₃₋₆cycloalkyl,
- (4) -C₂₋₆cycloheteroalkyl,
- (5) aryl, and
- (6) heteroaryl,

wherein each alkyl, alkenyl, cycloalkyl, cycloheteroalkyl, aryl and heteroaryl is unsubstituted or substituted with one to three substituents independently selected from: -C₁₋₆alkyl, -C₃₋₆cycloalkyl, -OH, -OC₁₋₆alkyl, -OC₃₋₆cycloalkyl, halogen, cyano, and -S(O)₂CH₃;

25

each R^m is independently selected from the group consisting of:

- (1) hydrogen, and
- 30 (2) -C₁₋₆alkyl;

each n is independently 0, 1, 2, 3 or 4;

each m is independently 0, 1 or 2;

each p is independently 0, 1, 2, 3 or 4;

35 each q is independently 0 or 1; and

each r is independently 0 or 1.

2. The compound according to Claim 1 wherein R² is hydrogen; or a pharmaceutically acceptable salt thereof.

~~3. The compound according to Claim 1 wherein A is heteroaryl, wherein heteroaryl is unsubstituted or substituted with one to four substituents selected from R^a; or a pharmaceutically acceptable salt thereof.~~

~~4. The compound according to Claim 1 wherein A is selected from the group consisting of:~~

- ~~(1) pyridine,~~
- ~~(2) pyrimidine,~~
- ~~(3) pyrazine,~~
- ~~(4) indazole,~~
- ~~(5) imidazo[1,2-a]pyridine,~~
- ~~(6) pyrrolo[3,2-c]pyridine,~~
- ~~(7) pyrrolo[2,3-b]pyridine,~~
- ~~(8) pyrazole,~~
- ~~(9) thiophene, and~~
- ~~(10) 1,2,4-oxadiazole,~~

~~wherein A is unsubstituted or substituted with one to four substituents selected from R^a; or a pharmaceutically acceptable salt thereof.~~

53. The compound according to Claim 1 wherein A is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^a; or a pharmaceutically acceptable salt thereof.

64. The compound according to Claim 1 wherein B is selected from the group consisting of:

- (1) pyrazine,
- (2) pyridine,
- (3) pyrimidine, and
- (4) pyridazine,

wherein each B is unsubstituted or substituted with one to three substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

75. The compound according to Claim 1 wherein B is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine, and
- (3) pyridazine,

wherein each B is unsubstituted or substituted with one to three substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

86. The compound according to Claim 1 wherein B is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^b; or a pharmaceutically acceptable salt thereof.

~~9. The compound according to Claim 1 wherein R¹ is selected from the group consisting of:~~

- ~~(1) —SO₂NH₂;~~
- ~~(2) —SO₂C₁₋₆alkyl;~~
- ~~(3) —SO₂NH-C₁₋₆alkyl;~~
- ~~(4) —SO₂C₃₋₆cycloalkyl;~~
- ~~(5) —C(O)NH₂;~~
- ~~(6) —CO₂H;~~
- ~~(7) —CN;~~
- ~~(8) —halogen;~~
- ~~(9) —OH;~~
- ~~(10) —OC₁₋₆alkyl;~~
- ~~(11) —C₁₋₆alkyl; and~~
- ~~(12) —CF₃;~~

~~wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one to three substituents selected from R^d; or a pharmaceutically acceptable salt thereof.~~

107. The compound according to Claim 1 wherein R¹ is selected from the group consisting of:

- (1) —SO₂NH₂,
- (2) —C(O)NH₂, and
- (3) —OH;

or a pharmaceutically acceptable salt thereof.

~~118~~. The compound according to Claim 1 wherein R³ is selected from the group consisting of: a monocyclic, bicyclic or spirocyclic C₃₋₈cycloalkyl ring, and a monocyclic, bicyclic or spirocyclic C₂₋₁₂cycloheteroalkyl ring, wherein the cycloheteroalkyl contains 1-4 heteroatoms independently selected from N(R^m), O, and S, and wherein each cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to eight substituents selected from R^C; or a pharmaceutically acceptable salt thereof.

~~129~~. The compound according to Claim 1 wherein R³ is a monocyclic, bicyclic or spirocyclic C₂₋₁₂cycloheteroalkyl ring, wherein the cycloheteroalkyl contains a nitrogen and 0-3 heteroatoms independently selected from N(R^m), O, and S, and wherein each cycloheteroalkyl is unsubstituted or substituted with one to eight substituents selected from R^C; or a pharmaceutically acceptable salt thereof.

~~1310~~. The compound according to Claim 1 wherein R³ is selected from the group consisting of:

- (1) cyclohexane,
- (2) cycloheptane,
- (3) pyrrolidine,
- (4) azetidine,
- (5) piperidine,
- (6) piperazine,
- (7) azepane,
- (8) morpholine,
- (9) thiomorpholine,
- (10) oxazepane,
- (11) isoindoline,
- (12) dihydroisoquinoline,
- (13) azabicyclo[2.2.1]heptane,
- (14) azabicyclo[3.1.1]heptane,
- (15) azabicyclo[4.1.0]heptane,
- (16) azabicyclo[3.2.1]octane,
- (17) azabicyclo[3.2.0]heptane,
- (18) azaspiro[2.5]octane,
- (19) dihydrothieno[3,2-c]pyridine,
- (20) dihydroimidazo[1,2-a]pyrazine, and

(21) hexahydrofuro[3,2-b]pyrrole,
wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^C;
or a pharmaceutically acceptable salt thereof.

5 ~~14~~11. The compound according to Claim 1 wherein R³ is selected from the group
consisting of:

- (1) pyrrolidine,
- (2) azetidine,
- (3) piperidine,
- 10 (4) piperazine,
- (5) azepane,
- (6) morpholine,
- (7) thiomorpholine,
- (8) oxazepane,
- 15 (9) isoindoline,
- (10) dihydroisoquinoline,
- (11) azabicyclo[2.2.1]heptane,
- (12) azabicyclo[3.1.1]heptane,
- (13) azabicyclo[4.1.0]heptane,
- 20 (14) azabicyclo[3.2.1]octane,
- (15) azabicyclo[3.2.0]heptane,
- (16) azaspiro[2.5]octane,
- (17) dihydrothieno[3,2-c]pyridine,
- (18) dihydroimidazo[1,2-a]pyrazine, and
- 25 (19) hexahydrofuro[3,2-b]pyrrole,

wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^C;
or a pharmaceutically acceptable salt thereof.

30 ~~15~~12. The compound according to Claim 1 wherein R³ is selected from the group
consisting of:

- (1) piperidine,
- (2) azepane, and
- (3) morpholine,

wherein R³ is unsubstituted or substituted with one to six substituents selected from R^C;
35 or a pharmaceutically acceptable salt thereof.

~~16~~13. The compound according to Claim 1 wherein

A is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine,
- (3) pyrazine,
- (4) indazole,
- (5) imidazo[1,2-a]pyridine,
- (6) pyrrolo[3,2-c]pyridine,
- (7) pyrrolo[2,3-b]pyridine,
- (8) pyrazole,
- (9) thiophene, and
- (10) 1,2,4-oxadiazole,

wherein A is unsubstituted or substituted with one to four substituents selected from R^a;

B is selected from the group consisting of:

- (1) pyridine,
- (2) pyrimidine, and
- (3) pyridazine,

wherein each B is unsubstituted or substituted with one to four substituents selected from R^b;

R¹ is selected from the group consisting of:

- (1) -SO₃H,
- (2) -SO₂NH₂,
- (3) -SO₂C₁₋₆alkyl,
- (4) -SO₂NH-C₁₋₆alkyl,
- (5) -SO₂C₃₋₆cycloalkyl,
- (6) -C(O)NH₂,
- (7) -CO₂H,
- (8) -CN,
- (9) halogen,
- (10) -OH,
- (11) -OC₁₋₆alkyl, and
- (12) -C₁₋₆alkyl, ~~and~~
- ~~(13) -CF₃,~~

wherein each alkyl, and cycloalkyl is unsubstituted or substituted with one ~~to three~~ substituents selected from R^d;

R² is hydrogen;

R³ is selected from the group consisting of:

- (1) pyrrolidine,
- (2) azetidine,
- 5 (3) piperidine,
- (4) piperazine,
- (5) azepane,
- (6) morpholine,
- (7) thiomorpholine,
- 10 (8) oxazepane,
- (9) isoindoline,
- (10) dihydroisoquinoline,
- (11) azabicyclo[2.2.1]heptane,
- (12) azabicyclo[3.1.1]heptane,
- 15 (13) azabicyclo[4.1.0]heptane,
- (14) azabicyclo[3.2.1]octane,
- (15) azabicyclo[3.2.0]heptane,
- (16) azaspiro[2.5]octane,
- (17) dihydrothieno[3,2-c]pyridine,
- 20 (18) dihydroimidazo[1,2-a]pyrazine, and
- (19) hexahydrofuro[3,2-b]pyrrole,

wherein R³ is unsubstituted or substituted with one to eight substituents selected from R^C; or a pharmaceutically acceptable salt thereof.

25 ~~17~~14. The compound according to Claim 1 wherein

A is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^a;

30 B is pyridine, wherein pyridine is unsubstituted or substituted with one to three substituents selected from R^b;

R¹ is selected from the group consisting of:

- (1) -SO₂NH₂,
- (2) -C(O)NH₂, and
- (3) -OH;

35 R² is hydrogen;

R³ is selected from the group consisting of:

- (1) piperidine,

(2) azepane, and

(3) morpholine,

wherein R³ is unsubstituted or substituted with one to six substituents selected from RC;
or a pharmaceutically acceptable salt thereof.

5

~~1815.~~ The A compound ~~according to Claim 1~~ selected from:

- 1) 2-(4,4-difluoropiperidin-1-yl)-N-(6-sulfamoylpyrazin-2-yl)-5-(trifluoromethyl)-nicotinamide;
- 2) 2-(4,4-difluoropiperidin-1-yl)-N-(4-hydroxypyrimidin-2-yl)-5-(trifluoromethyl)-nicotinamide;
- 3) 5-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
- 4) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)picolinic acid;
- 5) N-(6-cyanopyridin-3-yl)-2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamide;
- 6) 2-(azepan-1-yl)-N-(5-(methylsulfonyl)pyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 7) 2-(3-(hydroxymethyl)piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 8) 2-(azepan-1-yl)-N-(5-carbamoylpyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 9) 2-(4,4-difluoro-1-piperidyl)-6-methyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 10) 5-chloro-2-(4,4-difluoro-1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 11) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(5-sulfamoylpyridin-3-yl)nicotinamide;
- 12) 5,6-dicyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 13) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 14) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 15) 5-cyclobutyl-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 16) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 17) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 18) 6-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 19) 2-(4,4-difluoroazepan-1-yl)-5,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 20) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide;

- 21) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 22) 6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 23) 5-chloro-6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 24) 6-cyclobutyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 25) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 26) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 27) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-nicotinamide;
- 28) 2-(5,5-Difluoro-2-oxoazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 29) 2-(4,4-Dichloropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 31) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;
- 32) 5-chloro-2-(4,4-difluoroazepan-1-yl)-4,6-dimethyl-N-[1-(methylsulfonyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide;
- 33) N-{1-[(2-aminoethyl)sulfonyl]-1H-pyrazol-4-yl}-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methylpyridine-3-carboxamide;
- 34) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-indazol-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35) 2-(4,4-difluoroazepan-1-yl)-N-[1-(methylsulfonyl)-1H-pyrrolo[3,2-c]pyridin-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 36) N-[1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 37) N-[5-cyclopropyl-1-(methylsulfonyl)-1H-pyrazol-4-yl]-2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 38) 2-cyclopropyl-4-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;
- 39) 6-cyclopropyl-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyridazine-4-carboxamide;
- 40) 6-methyl-N-(2-sulfamoylpyridin-4-yl)-2-(3,4,4-trifluoroazepan-1-yl)nicotinamide;

- 41) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 42) N-[2-(tert-butylsulfamoyl)pyridin-4-yl]-5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methoxy-pyridine-3-carboxamide;
- 5 43) 5-cyano-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;
- 44) 5-(cyclopropylethynyl)-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 45) 2-(azepan-1-yl)-N-(3-cyano-1,2,4-oxadiazol-5-yl)-5-(trifluoromethyl)pyridine-3-
10 carboxamide;
- 46) 5-(cyclopropylmethyl)-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 47) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoro-methyl)nicotinamide;
- 15 48) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoro-methyl)-nicotinamide;
- 49) (R)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoro-methyl)nicotinamide;
- 50) (S)-2-(4,4-dichloro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoro-methyl)nicotinamide;
- 20 51) 2-(4,4-Dichloroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 52) 2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 25 53) 5-chloro-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-6-methyl-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 54) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 55) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 30 56) (S)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 57) (R)-2-(3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 35 58) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1S,5S)-1-(trifluoromethyl)-3-aza-bicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;

- 59) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[(1R,5R)-1-(trifluoromethyl)-3-aza-bicyclo[3.2.0]heptan-3-yl]pyridine-3-carboxamide;
- 60) N-(2-sulfamoylpyridin-4-yl)-2-((1R,5S)-6,6,7,7-tetrafluoro-3-azabicyclo[3.2.0]heptan-3-yl)-5-(trifluoromethyl)nicotinamide;
- 5 61) 2-[(1S,6S)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 62) 2-[(1R,6R)-7,7-difluoro-6-methyl-3-azabicyclo[4.1.0]heptan-3-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 63) 2-((1R,5S)-8,8-difluoro-3-oxaoctan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 10 (trifluoromethyl)nicotinamide;
- 64) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 65) 2-((1S,5R)-6,6-difluoro-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 66) (R)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 67) (S)-2-(1,1-difluoro-5-azaspiro[2.5]octan-5-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 68) 2-((1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 20 (trifluoromethyl)nicotinamide;
- 69) 2-((1S,6S)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 70) 2-((1R,6R)-7,7-difluoro-3-azabicyclo[4.1.0]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 25 71) 2-[(1R,4R)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 72) 2-[(1S,4S)-5,5-difluoro-2-azabicyclo[2.2.1]heptan-2-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 73) (R)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-
- 30 (trifluoromethyl)nicotinamide;
- 74) (S)-2-(4,4-difluoro-2-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 75) 2-((3R,4s,5S)-4-hydroxy-3,4,5-trimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 35 76) 2-((1R,5S)-6,6-difluoro-3-azabicyclo[3.1.1]heptan-3-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

- 77) 2-[(3S,4S)-4-hydroxy-3-methyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 78) 2-[(3S,4r,5R)-4-hydroxy-3,5-dimethyl-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 5 79) 2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 80) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 81) 2-[3-(3,5-difluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 10 82) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-(trifluoromethyl)-1-piperidyl]pyridine-3-carboxamide;
- 83) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[[4-(trifluoromethyl)phenyl]methyl]-1-piperidyl]pyridine-3-carboxamide;
- 15 84) N-(2-sulfamoyl-4-pyridyl)-2-thiomorpholino-5-(trifluoromethyl)pyridine-3-carboxamide;
- 85) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]pyridine-3-carboxamide;
- 86) 2-(3-benzyl-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-7-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 87) 2-[3,3-dimethyl-4-(2,2,2-trifluoroethyl)piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 88) 2-(2,2-dimethylmorpholin-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 89) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[8-(trifluoromethyl)-3,4-dihydro-1H-isoquinolin-2-yl]pyridine-3-carboxamide;
- 25 90) N-(2-sulfamoyl-4-pyridyl)-2-[4-(trifluoromethoxy)isoindolin-2-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 91) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[2-[4-(trifluoromethyl)phenyl]morpholin-4-yl]pyridine-3-carboxamide;
- 30 92) N-(2-sulfamoyl-4-pyridyl)-2-(3,3,4,4-tetrafluoropyrrolidin-1-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 93) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)azetidin-1-yl]pyridine-3-carboxamide;
- 94) 2-(3-pyrazol-1-ylpyrrolidin-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 95) 2-[2-(4-fluorophenyl)-1-piperidyl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 96) 2-(2,3,3a,5,6,6a-hexahydrofuro[3,2-b]pyrrol-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoro-methyl)pyridine-3-carboxamide;
- 97) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[3-[4-(trifluoromethyl)phenoxy]azetidin-1-yl]pyridine-3-carboxamide;
- 5 98) N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-2-[4-[3-(trifluoromethyl)phenoxy]-1-piperidyl]pyridine-3-carboxamide;
- 99) 2-[4-(cyclopropylmethyl)-3-oxo-piperazin-1-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 100) N-(2-sulfamoyl-4-pyridyl)-2-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 10 101) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 102) 2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 103) 2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 104) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 105) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 20 106) 2-[(2R)-6,6-dimethyl-2-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 107) 2-(2,2-dimethyl-1,4-oxazepan-4-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 108) 2-[(7S)-7-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 25 109) N-[2-(tert-butylsulfamoyl)-4-pyridyl]-5-chloro-2-(4,4-difluoroazepan-1-yl)pyridine-3-carboxamide;
- 110) 2-[(2S)-2-methylmorpholin-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 30 111) 2-[(2R)-2-methyl-1,4-oxazepan-4-yl]-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 112) 2-(3-hydroxy-3-methyl-1-piperidyl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 113) 2-(6-fluoro-1,1-dimethyl-isoindolin-2-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 35 114) 2-(azepan-1-yl)-N-(2-methyl-5-sulfamoylthiophen-3-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 115) 2-(4,4-difluoro-5-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 116) 5-chloro-2-[(7R)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 5 117) 5-chloro-2-[(7S)-7-(difluoromethyl)-1,4-oxazepan-4-yl]-6-methyl-N-(2-sulfamoylpyridin-4-yl)pyridine-3-carboxamide;
- 118) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 119) (S)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(7-(trifluoromethyl)-1,4-oxazepan-4-yl)nicotinamide;
- 10 120) 2-[(2S,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl]-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 121) 2-((2R,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 15 122) 2-((2R,7R)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 123) 2-((2S,7S)-2-methyl-7-(trifluoromethyl)-1,4-oxazepan-4-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 124) (S)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 20 125) (R)-5-chloro-2-(2-(difluoromethyl)morpholino)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 126) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[(2S)-2-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;
- 25 127) (R)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-(2-(trifluoromethyl)pyrrolidin-1-yl)nicotinamide;
- 128) N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-2-[3-(trifluoromethyl)pyrrolidin-1-yl]pyridine-3-carboxamide;
- 129) (S)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 30 130) (R)-2-(3-cyanopyrrolidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 131) 2-(4,4-difluoro-3-methylazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 35 132) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;

- 133) 2-((2R,6S)-2-ethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 134) 2-((2S,6R)-2-ethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 5 135) (R)-2-(2,2-dimethyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 136) (S)-2-(2,2-dimethyl-6-(trifluoromethyl)-morpholino)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 137) 4-(2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
- 10 138) 6-chloro-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)pyridine-3-carboxamide;
- 139) 2-(azepan-1-yl)-N-(2-sulfamoyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 140) 2-(azepan-1-yl)-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 141) 2-(azepan-1-yl)-N-(6-sulfamoyl-2-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 15 142) 2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 143) N-(2-methoxypyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)nicotinamide;
- 144) 2-(4,4-difluoroazepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 20 145) 2-(azepan-1-yl)-N-(5-sulfamoyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 146) 2-(4,4-difluoroazepan-1-yl)-N-(2-methoxy-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 147) 2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-(methylsulfonyl)pyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 25 148) 2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 149) 2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 150) N-(2-cyano-4-pyridyl)-2-[(3S,5R)-4,4-difluoro-3,5-dimethyl-1-piperidyl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 30 151) N-(2-methylsulfonyl-4-pyridyl)-2-[(1R,5S)-6,6,7,7-tetrafluoro-3-azabicyclo[3.2.0]heptan-3-yl]-5-(trifluoromethyl)pyridine-3-carboxamide;
- 152) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-methylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 35 153) 2-[(1R,5S)-3-azabicyclo[3.2.0]heptan-3-yl]-N-(2-cyano-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;

- 154) (R)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-nicotinamide;
- 155) (S)-N-(2-cyanopyridin-4-yl)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-5-(trifluoromethyl)-nicotinamide;
- 5 156) 4-(2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)-picolinamide;
- 157) N-(2-carbamoyl-4-pyridyl)-2-[(3S)-4,4-difluoro-3-methyl-1-piperidyl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 158) N-(2-carbamoyl-4-pyridyl)-2-[(3R)-4,4-difluoro-3-methyl-1-piperidyl]-5-(trifluoromethyl)-pyridine-3-carboxamide;
- 10 159) 2-(4,4-difluoropiperidin-1-yl)-4-methoxy-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 160) 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 161) 5-chloro-6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 15 162) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 163) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 20 164) (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 165) (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)nicotinamide;
- 166) 6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 25 167) 6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 168) 6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 30 169) 5-chloro-6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 170) 6-chloro-2-(4,4-difluoropiperidin-1-yl)-4-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 171) 2-(4,4-difluoroazepan-1-yl)-5-(difluoromethoxy)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 35 172) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

- 173) 4-(4,4-difluoroazepan-1-yl)-2-methyl-N-(2-sulfamoylpyridin-4-yl)pyrimidine-5-carboxamide;
- 174) 2-(4,4-difluoroazepan-1-yl)-6-(difluoromethyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 5 175) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 176) 4-(2-(4,4-difluoropiperidin-1-yl)-5-(trifluoromethyl)nicotinamido)pyridine-2-sulfonic acid;
- 177) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethoxy)nicotinamide
- 10 178) 2-(4,4-difluoropiperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 179) 3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide;
- 15 180) 5-(tert-butyl)-2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 181) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethyl)-nicotinamide;
- 182) 5-cyclopropyl-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-6-(trifluoromethoxy)-nicotinamide;
- 20 183) 2-(4,4-difluoropiperidin-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(2,2,2-trifluoroethoxy)-nicotinamide;
- 184) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
- 25 185) 6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 186) 2-(azepan-1-yl)-N-(5-fluoropyridin-3-yl)-5-(trifluoromethyl)nicotinamide;
- 187) 2-(azepan-1-yl)-5-chloro-N-(2-methoxy-4-pyridyl)-4,6-dimethyl-pyridine-3-carboxamide;
- 30 188) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 189) 5-chloro-2-(4,4-difluoro-1-piperidyl)-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 190) 2-(6-azaspiro[2.5]octan-6-yl)-5-chloro-4,6-dimethyl-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
- 35 191) 5-chloro-4,6-dimethyl-2-(1-piperidyl)-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;

- 192) 2-(4,4-difluoroazepan-1-yl)-6-methoxy-N-(5-sulfamoyl-3-pyridyl)pyridine-3-carboxamide;
 - 193) 2-(azepan-1-yl)-N-(5-cyano-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 194) 2-(azepan-1-yl)-N-(5-methoxy-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
- 5
- 195) 2-(azepan-1-yl)-N-(5-methyl-3-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 196) 2-(azepan-1-yl)-N-[5-(hydroxymethyl)-3-pyridyl]-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 197) 2-(azepan-1-yl)-N-(2-cyano-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 10 198) 2-(azepan-1-yl)-N-(2-ethylsulfonyl-4-pyridyl)-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 199) 2-(azepan-1-yl)-N-(3-bromoimidazo[1,2-a]pyridin-6-yl)-5-(trifluoromethyl)pyridine-3-carboxamide;
 - 200) 2-(azepan-1-yl)-5-(trifluoromethyl)-N-[5-(trifluoromethyl)-3-pyridyl]pyridine-3-carboxamide;
- 15
- 201) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
 - 202) 5-chloro-4,6-dimethyl-2-(6-azaspiro[2.5]octan-6-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
 - 203) 4-(2-(azepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
 - 20 204) 5-bromo-2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
 - 205) 2-(4,4-difluoropiperidin-1-yl)-5-phenyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
 - 206) 2-(4,4-difluoropiperidin-1-yl)-5-(piperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
 - 207) 2-(4,4-difluoropiperidin-1-yl)-5-(1H-pyrazol-1-yl)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;
- 25
- 208) N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)-5-(trifluoromethyl)-nicotinamide;
 - 209) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(6-azaspiro[2.5]octan-6-yl)nicotinamide;
 - 30 210) 2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)-nicotinamide;
 - 211) 5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)-2-(piperidin-1-yl)nicotinamide;
 - 212) 2-(azepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)-5-(trifluoromethyl)nicotinamide; and
 - 35 213) 2-(azepan-1-yl)-5-chloro-4,6-dimethyl-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide;
- or a pharmaceutically acceptable salt thereof.

~~1916.~~ ~~The A~~ compound ~~according to Claim 1~~ selected from:

- 1) 5-chloro-2-(4,4-difluorocyclohexyl)-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 2) 5-chloro-2-cycloheptyl-4,6-dimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide
- 3) 5-chloro-3-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)pyrazine-2-carboxamide;
- 4) 5-chloro-4,6-dimethyl-2-(4-methylcyclohexyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide; and
- 5) 5-chloro-2-(4,4-difluoroazepan-1-yl)-N,4,6-trimethyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;

or a pharmaceutically acceptable salt thereof.

~~2017.~~ A pharmaceutical composition comprising a compound of any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

~~21.~~ ~~The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for the treatment of a disorder, condition, or disease that is responsive to the inhibition of Na_v1.8 channel activity in a mammal in need thereof.~~

~~2218.~~ The use of a compound of any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof, ~~for in~~ the manufacture of a medicament for the treatment, prevention or control of a pain disorder, a cough disorder, an acute itch disorder or chronic itch disorder.

~~2319.~~ The use of Claim ~~22-18~~ wherein the disorder is a pain disorder.

~~2420.~~ The use of Claim ~~23-19~~ wherein the pain disorder is selected from: acute pain, inflammatory pain, or neuropathic pain.

~~2521.~~ A compound according to any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof, for use in therapy.

~~2622.~~ ~~The A~~ compound ~~according to Claim 1~~ selected from:

- 1) (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 2) (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 3) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-nicotinamide;

- 4) 2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 5) 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 6) 5-chloro-6-cyclobutyl-2-((2S,6R)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 7) 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 8) 2-(4,4-difluoroazepan-1-yl)-6-(difluoromethyl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 9) 2-(4,4-difluoropiperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 10) 2-(4,4-difluoropiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;
- 11) 5-chloro-6-cyclobutyl-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)nicotinamide;
- 12) 4-(2-(4,4-difluoroazepan-1-yl)-5-(trifluoromethyl)nicotinamido)picolinamide;
- 13) 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; and
- 14) 2-(4,4-difluoroazepan-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide;

or a pharmaceutically acceptable salt thereof.

2723. The A compound ~~according to Claim 1~~ which is (S)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide; or a pharmaceutically acceptable salt thereof.

2824. The A compound ~~according to Claim 1~~ which is (R)-2-(4,4-difluoro-3-methylpiperidin-1-yl)-N-(2-sulfamoylpyridin-4-yl)-5-(trifluoromethyl)nicotinamide; or a pharmaceutically acceptable salt thereof.

2925. A ~~The~~ compound ~~according to Claim 1~~ which is 5-chloro-6-cyclobutyl-2-((2R,6S)-2-methyl-6-(trifluoromethyl)morpholino)-N-(2-sulfamoylpyridin-4-yl)-nicotinamide; or a pharmaceutically acceptable salt thereof.

3026. The A compound ~~according to Claim 1~~ which is 2-(4,4-difluoro-piperidin-1-yl)-5-fluoro-6-methyl-N-(2-sulfamoylpyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.

3127. The A compound ~~according to Claim 1~~ which is 5-chloro-6-cyclopropyl-2-(4,4-difluoroazepan-1-yl)-N-(2-oxo-1,2-dihydropyridin-4-yl)nicotinamide; or a pharmaceutically acceptable salt thereof.